Homology Medicines is a genetic medicines company. Co.'s proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors to deliver single administration genetic medicines in vivo either through its gene therapy, Co.'s nuclease-free gene editing modality, or Co.'s gene therapy to express antibodies platform. Co.'s clinical programs include: HMI-102, an investigational gene therapy candidate in clinical development for the treatment of adult patients with phenylketonuria; as well as HMI-103, an investigational gene editing candidate in clinical development for the treatment of patients with PKU. The FIXX stock yearly return is shown above.
The yearly return on the FIXX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the FIXX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|